CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 61 enrolled
Drug / intervention
Propranolol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04692844
NCT04692844N/ACompleted

The Mechanism of Tremor Modulating Properties of Propranolol and Primidone in Essential Tremor: A Study With Transcranial Magnetic Stimulation and Eye Blink Classical Conditioning Paradigm

University Medical Centre Ljubljana·observational·Posted Jan 5, 2021·Updated Apr 13, 2023

In Brief

An observational study evaluating Propranolol and Primidone for Essential Tremor. Completed, enrolled 61 participants across 1 site.

Detailed Summary

Pathophysiology of tremor-modulating mechanisms of propranolol and primidone in essential tremor (ET) will be studied using accelerometry with electromyography (EMG), transcranial magnetic stimulation (TMS), and eyeblink conditioning paradigm (EBCC). TMS is a well-established experimental method for studying the effects of drugs on motor cortex excitability. EBCC is a learning paradigm that can be used for studying cerebellar dysfunction since only brainstem and cerebellar functions seem to be needed for this paradigm. The investigators will use TMS to study the mechanisms of primidone and propranolol action in ET, EBCC paradigm to evaluate cerebellar dysfunction in ET patients and to show whether cerebellar dysfunction influences the effectiveness of propranolol and primidone. The investigators will clinically assess patients using The Essential Tremor Rating Assessment Scale (TETRAS) and the Scale for the Assessment and Rating of Ataxia (SARA) scales. Patients with ET will be studied prior to treatment with propranolol or primidone and re-tested 3-6 months after treatment initiation. On each visit, the investigators will clinically assess the patients and perform accelerometry, TMS measurements, and the eyeblink classical conditioning (EBCC) paradigm. The investigators hypothesize that in ET patients, baseline electrophysiological parameters will differ between responders and non-responders to propranolol and primidone and that propranolol and primidone will cause a different pattern of change in electrophysiological parameters among responders. It is hypothesized that cerebellar dysfunction will negatively correlate with patients' response to treatment.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSlovenia
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedJan 5, 2021
Enrollment StartAug 28, 2017
Primary CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 5.5 years ago

Interventions

Propranololdrug

Patients will receive Propranolol in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.

Primidonedrug

Patients will receive Primidone in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.